Centrus Energy Corp. (LEU) completed its uplisting from NYSE American to the New York Stock Exchange on December 1, 2025. Trading on NYSE American will end after the close on December 3, 2025, and the company’s shares will begin trading on the NYSE at the opening on December 4, 2025, under the same ticker symbol, LEU.
The move to the NYSE is a strategic milestone that expands Centrus’s liquidity base and places the company alongside larger, more established peers. By listing on the NYSE, Centrus gains greater visibility among institutional investors, which can support future capital‑raising initiatives and enhance its ability to secure financing for its planned expansion of the Piketon, Ohio enrichment facility.
Centrus reported Q3 2025 results that included a net income of $3.9 million, or $0.19 diluted earnings per share, on revenue of $74.9 million. The earnings per share beat analyst expectations of $0.08 by $0.11, a 138% over‑performance, driven by disciplined cost management and a favorable mix shift toward the higher‑margin Technical Solutions segment. Revenue grew 30% year‑over‑year, supported by a 44% increase in Low‑Enriched Uranium (LEU) sales and a 20% rise in Technical Solutions revenue, reflecting strong demand from both commercial and government customers.
Segment analysis shows that the LEU division generated $44.8 million in revenue, up 44% from $30.5 million in Q3 2024, while the Technical Solutions segment produced $30.1 million, up 20% from $25.1 million. The higher contribution from Technical Solutions, which includes services such as fuel fabrication and waste management, helped offset the lower margin of the LEU segment and contributed to the overall earnings beat.
Management highlighted the uplisting as a key enabler for Centrus’s long‑term growth strategy. CFO Todd Tinelli noted that the NYSE listing “provides improved liquidity for shareholders while enhancing visibility to a broader investor base as we work to restore America’s ability to enrich uranium at a large scale.” CEO Amir Vexler emphasized that the company’s expansion plans, contingent on federal funding, will increase domestic production of both low‑assay and high‑assay low‑enriched uranium, positioning Centrus to meet growing demand for next‑generation nuclear reactors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.